Akouos, Inc. Logo

Akouos, Inc.

AKUS

(1.0)
Stock Price

13,29 USD

-31.09% ROA

-31.85% ROE

-2.69x PER

Market Cap.

0,00 USD

12.4% DER

0% Yield

0% NPM

Akouos, Inc. Stock Analysis

Akouos, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Akouos, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (20%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (2.71x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

The stock's ROE indicates a negative return (-34.93%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-30.35%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Akouos, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Akouos, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Unknown
2 MACD Unknown
3 RSI Unknown
4 Stoch RSI Unknown

Akouos, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Akouos, Inc. Revenue
Year Revenue Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Akouos, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 5.644.000
2019 20.473.000 72.43%
2020 34.297.000 40.31%
2021 64.595.000 46.9%
2022 55.748.000 -15.87%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Akouos, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 1.776.000
2019 3.410.000 47.92%
2020 14.583.000 76.62%
2021 22.226.000 34.39%
2022 25.068.000 11.34%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Akouos, Inc. EBITDA
Year EBITDA Growth
2018 -5.958.000
2019 -25.044.000 76.21%
2020 -46.425.000 46.05%
2021 -82.924.000 44.02%
2022 -73.176.000 -13.32%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Akouos, Inc. Gross Profit
Year Gross Profit Growth
2018 0
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Akouos, Inc. Net Profit
Year Net Profit Growth
2018 -6.013.000
2019 -25.741.000 76.64%
2020 -48.600.000 47.03%
2021 -86.671.000 43.93%
2022 -81.444.000 -6.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Akouos, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -1
2019 -4 100%
2020 -3 -100%
2021 -5 50%
2022 -2 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Akouos, Inc. Free Cashflow
Year Free Cashflow Growth
2018 -7.267.000
2019 -22.950.000 68.34%
2020 -45.300.000 49.34%
2021 -72.752.000 37.73%
2022 -23.703.000 -206.93%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Akouos, Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -6.735.000
2019 -19.510.000 65.48%
2020 -40.767.000 52.14%
2021 -63.733.000 36.03%
2022 -21.100.000 -202.05%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Akouos, Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 532.000
2019 3.440.000 84.53%
2020 4.533.000 24.11%
2021 9.019.000 49.74%
2022 2.603.000 -246.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Akouos, Inc. Equity
Year Equity Growth
2018 -7.229.000
2019 -32.801.000 77.96%
2020 310.614.000 110.56%
2021 233.650.000 -32.94%
2022 180.838.000 -29.2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Akouos, Inc. Assets
Year Assets Growth
2018 25.778.000
2019 45.162.000 42.92%
2020 333.350.000 86.45%
2021 278.755.000 -19.59%
2022 225.509.000 -23.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Akouos, Inc. Liabilities
Year Liabilities Growth
2018 33.007.000
2019 77.963.000 57.66%
2020 22.736.000 -242.91%
2021 45.105.000 49.59%
2022 44.671.000 -0.97%

Akouos, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-4.94
Price to Earning Ratio
-2.69x
Price To Sales Ratio
0x
POCF Ratio
-3.66
PFCF Ratio
0
Price to Book Ratio
1
EV to Sales
0
EV Over EBITDA
1.12
EV to Operating CashFlow
1.46
EV to FreeCashFlow
1.28
Earnings Yield
-0.37
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
-0,09 Bil.
Graham Number
38.46
Graham NetNet
10.67

Income Statement Metrics

Net Income per Share
-4.94
Income Quality
0.74
ROE
-0.32
Return On Assets
-0.31
Return On Capital Employed
-0.33
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.63
Free CashFlow per Share
-4.15
Capex to Operating CashFlow
0.14
Capex to Revenue
0
Capex to Depreciation
-2.41
Return on Invested Capital
-0.3
Return on Tangible Assets
-0.31
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0.51

Balance Sheet

Cash per Share
13,24
Book Value per Share
13,31
Tangible Book Value per Share
13.31
Shareholders Equity per Share
13.31
Interest Debt per Share
1.65
Debt to Equity
0.12
Debt to Assets
0.1
Net Debt to EBITDA
1.12
Current Ratio
14.06
Tangible Asset Value
0,23 Bil.
Net Current Asset Value
0,19 Bil.
Invested Capital
0.12
Working Capital
0,22 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Akouos, Inc. Dividends
Year Dividends Growth

Akouos, Inc. Profile

About Akouos, Inc.

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

CEO
Dr. Emmanuel Simons M.B.A., P
Employee
103
Address
645 Summer Street
Boston, 02210

Akouos, Inc. Executives & BODs

Akouos, Inc. Executives & BODs
# Name Age
1 Dr. Luk H. Vandenberghe M.D., Ph.D.
Founder & Member of Scientific Advisory Board
70
2 Dr. Emmanuel Simons M.B.A., Ph.D.
Co- Founder, Pres, Chief Executive Officer & Director
70
3 Mr. William F. Sewell Ph.D.
Founder & Member of Scientific Advisory Board
70
4 Mr. Richard Smith M.D.
Founder & Member of Scientific Advisory Board
70
5 Ms. Sachiyo Minegishi
Chief Financial Officer, Treasurer, Assistant Sec. & Principal Accounting Officer
70
6 Dr. Michael John McKenna M.D.
Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board
70
7 Dr. Karoline K. Shair
Senior Vice President, Gen. Counsel, Chief Legal Officer & Corporation Sec.
70
8 Dr. Aaron Tward M.D., Ph.D.
Chief Scientific Officer
70
9 Ms. Stacy Price
Chief Technical Officer
70
10 Ms. Jennifer Anne Wellman M.S.
Chief Operating Officer
70

Akouos, Inc. Competitors